Shareholding for the Period Ended March 31, 2018
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here13-04-2018
13-04-2018
Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 027252 Name of the Signatory :- PRAJEET NAIRDesignation :- Company Secretary and Compliance Officer11-04-2018
Compliance Certificate - Regulation 7(3) Of The SEBI (LODR) Regulations, 2015
In compliance with Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Certificate from the Company and the Registrar and Share Transfer Agent for the half year ended March 31, 2018.11-04-2018
Compliance Certificate - Regulation 40 (9) Of The SEBI (LODR) Regulations, 2015
In compliance with Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Certificate given by the Practicing Company Secretary, M/s. Manish Ghia & Associates, for the half year ended March 31, 2018.11-04-2018
GSK backs out of $20 bn bidding race for Pfizer's consumer health-care unit
Pfizer is the world's fifth-largest player in consumer health with 2.5 percent of a market bolstered by ageing populations and growing interest in health and wellness23-03-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, enclosed herewith are the details of the meeting scheduled with an Analyst/Institutional Investor. Please note that the enclosed schedule is subject to change on account of exigencies on the part of the Analyst/Institutional Investor or the Company. The enclosed schedule shall also be displayed on the website of the Company - www.pfizerindia.com in compliance with the Regulation 46 of the Listing Regulations.19-03-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, enclosed herewith are the details of the meeting scheduled with an Analyst/Institutional Investor. Please note that the enclosed schedule is subject to change on account of exigencies on the part of the Analyst/Institutional Investor or the Company. The enclosed schedule shall also be displayed on the website of the Company - www.pfizerindia.com in compliance with the Regulation 46 of the Listing Regulations.19-03-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, enclosed herewith are the details of the meeting scheduled with an Analyst/Institutional Investor. Please note that the enclosed schedule is subject to change on account of exigencies on the part of the Analyst/Institutional Investor or the Company. The enclosed schedule shall also be displayed on the website of the Company - www.pfizerindia.com in compliance with the Regulation 46 of the Listing Regulations.16-03-2018
Reckitt Benckiser stands by Mead Johnson deal, despite Pfizer option
The CEO told Reuters that the Mead Johnson acquisition had already benefited Reckitt, although it has only just reversed several quarters of decline in that business10-03-2018
Announcement under Regulation 30 (LODR)-Change in Directorate
We refer to our letter dated February 19, 2018, wherein it was intimated that Mr. Ravi Prakash Bhagavathula had tendered his resignation as Executive Director - Finance and Chief Financial Officer with effect from such date as may be agreed between Mr. Ravi Prakash Bhagavathula and the Board of Directors. In furtherance to the same, we would like to inform that Mr. Ravi Prakash Bhagavathula has resigned as Executive...01-03-2018